Literature DB >> 32961369

Clinical-Grade Expanded Regulatory T Cells Are Enriched with Highly Suppressive Cells Producing IL-10, Granzyme B, and IL-35.

Francesca Ulbar1, Ida Villanova2, Raffaella Giancola2, Stefano Baldoni1, Francesco Guardalupi1, Bianca Fabi1, Paola Olioso2, Anita Capone2, Rosaria Sola3, Sara Ciardelli3, Beatrice Del Papa3, Antonello Brattelli2, Ilda Ricciardi2, Stefano Taricani2, Giulia Sabbatinelli4, Ornella Iuliani2, Cecilia Passeri2, Paolo Sportoletti3, Stella Santarone2, Antonio Pierini3, Giuseppe Calabrese5, Franca Falzetti3, Tiziana Bonfini2, Patrizia Accorsi2, Loredana Ruggeri3, Massimo Fabrizio Martelli3, Andrea Velardi3, Mauro Di Ianni6.   

Abstract

In the setting of T cell-depleted, full-haplotype mismatched transplantation, adoptive immunotherapy with regulatory T cells (Tregs) and conventional T cells (Tcons) can prevent graft-versus-host disease (GVHD) and improve post-transplantation immunologic reconstitution and is associated with a powerful graft-versus-leukemia effect. To improve the purity and the quantity of the infused Tregs, good manufacturing practices (GMP)-compatible expansion protocols are needed. Here we expanded Tregs using an automated, clinical-grade protocol. Cells were extensively characterized in vitro, and their efficiency was tested in vivo in a mouse model. Tregs were selected by CliniMacs (CD4+CD25+, 94.5 ± 6.3%; FoxP3+, 63.7 ± 11.5%; CD127+, 20 ± 3%; suppressive activity, 60 ± 7%), and an aliquot of 100 × 106 was expanded for 14 days using the CliniMACS Prodigy System, obtaining 684 ± 279 × 106 cells (CD4+CD25+, 99.6 ± 0.2%; FoxP3+, 82 ± 8%; CD127+, 1.1 ± 0.8%; suppressive activity, 75 ± 12%). CD39 and CTLA4 expression levels increased from 22.4 ± 12% to 58.1 ± 13.3% (P < .05) and from 20.4 ± 6.7% to 85.4 ± 9.8% (P < .01), respectively. TIM3 levels increased from .4 ± .05% to 29 ± 16% (P < .05). Memory Tregs were the prevalent population, whereas naive Tregs almost disappeared at the end of the culture. mRNA analysis displayed significant increases in CD39, IL-10, granzyme B, and IL-35 levels at the end of culture period (P < .05). Conversely, IFNγ expression decreased significantly by day +14. Expanded Tregs were sorted according to TIM3, CD39, and CD62L expression levels (purity >95%). When sorted populations were analyzed, TIM3+ cells showed significant increases in IL-10 and granzyme B (P < .01) .When expanded Tregs were infused in an NSG murine model, mice that received Tcons only died of GVHD, whereas mice that received both Tcons and Tregs survived without GVHD. GMP grade expanded cells that display phenotypic and functional Treg characteristics can be obtained using a fully automated system. Treg suppression is mediated by multiple overlapping mechanisms (eg, CTLA-4, CD39, IL-10, IL-35, TGF-β, granzyme B). TIM3+ cells emerge as a potentially highly suppressive population. © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
Copyright © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical-grade expanded Tregs; GVHD; Graft versus leukemia; Immunotolerance; Tregs

Mesh:

Substances:

Year:  2020        PMID: 32961369     DOI: 10.1016/j.bbmt.2020.08.034

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  5 in total

1.  A Novel GMP Protocol to Produce High-Quality Treg Cells From the Pediatric Thymic Tissue to Be Employed as Cellular Therapy.

Authors:  Esther Bernaldo-de-Quirós; Beatriz Cózar; Rocío López-Esteban; Maribel Clemente; Juan Miguel Gil-Jaurena; Carlos Pardo; Ana Pita; Ramón Pérez-Caballero; Manuela Camino; Nuria Gil; María Eugenia Fernández-Santos; Susana Suarez; Marjorie Pion; Marta Martínez-Bonet; Rafael Correa-Rocha
Journal:  Front Immunol       Date:  2022-05-16       Impact factor: 8.786

2.  Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT.

Authors:  Annalisa Ruggeri; Myriam Labopin; Emanuele Angelucci; Didier Blaise; Fabio Ciceri; Yener Koc; Patrizia Chiusolo; Jose Luiz Diez-Martin; Zafer Gülbas; Luca Castagna; Benedetto Bruno; Mutlu Arat; Massimo Martino; Arnon Nagler; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2021-03-05       Impact factor: 5.174

Review 3.  Immune Reconstitution After Allogeneic Haematopoietic Cell Transplantation: From Observational Studies to Targeted Interventions.

Authors:  Asaf Yanir; Ansgar Schulz; Anita Lawitschka; Stefan Nierkens; Matthias Eyrich
Journal:  Front Pediatr       Date:  2022-01-11       Impact factor: 3.418

Review 4.  Different subpopulations of regulatory T cells in human autoimmune disease, transplantation, and tumor immunity.

Authors:  Zhongyi Jiang; Haitao Zhu; Pusen Wang; Weitao Que; Lin Zhong; Xiao-Kang Li; Futian Du
Journal:  MedComm (2020)       Date:  2022-04-21

Review 5.  Regulatory T Cells in GVHD Therapy.

Authors:  Wen-Wen Guo; Xiu-Hua Su; Ming-Yang Wang; Ming-Zhe Han; Xiao-Ming Feng; Er-Lie Jiang
Journal:  Front Immunol       Date:  2021-06-18       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.